Welcome to our dedicated page for Peraso SEC filings (Ticker: PRSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Peraso's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Peraso's regulatory disclosures and financial reporting.
Peraso Inc. reported that Nasdaq notified it on July 21, 2026 that its common stock no longer satisfies the Nasdaq Capital Market minimum $1 bid price requirement, based on the closing bid price for 30 consecutive business days ended July 20, 2026. Under Nasdaq rules, Peraso has 180 calendar days, until January 19, 2027, to regain compliance by achieving a closing bid of at least $1 per share for at least ten consecutive business days. If it still does not meet the standard, it may be eligible for an additional 180-day period if it meets other listing criteria and notifies Nasdaq of its intent to cure, including by a reverse stock split if necessary. The notice does not immediately remove the stock from Nasdaq, and the company is monitoring its share price and options.
The board also set September 10, 2026 as the date of the virtual 2026 annual meeting of stockholders, with a record date of July 20, 2026. Shareholder proposals, director nominations and universal proxy notices are due by 5:00 p.m. Eastern on August 3, 2026.
Peraso Inc. is registering the resale of up to 31,750,000 shares of common stock by Roth Principal Investments, LLC under a committed equity facility. Peraso may, at its sole discretion over up to 36 months, sell shares to Roth for up to $25,000,000, priced off VWAP with discounts of 3.0% for Market Open and Intraday purchases and 5.0% for Pre- and Post-Market purchases. Peraso receives proceeds only from its sales to Roth, not from Roth’s resales.
Nasdaq rules cap issuances to Roth at 3,004,114 shares (19.99%) unless shareholders approve more or the average purchase price is at least $0.9853, and Roth cannot exceed a 4.99% Beneficial Ownership Limitation. Peraso had 15,040,679 shares outstanding as of June 23, 2026; if all 31,750,000 shares were issued, they would represent 67.9% of outstanding shares and non-affiliate holdings as of that date. A $500,000 commitment fee and legal reimbursements are payable to Roth, and Peraso expects to use any net proceeds for working capital and general corporate purposes, including product development and expansion in drone, defense and tactical communications markets.
Peraso Inc. entered into a letter agreement with Roth Principal Investments, LLC on July 10, 2026, modifying terms of an existing Common Stock Purchase Agreement dated June 30, 2026. Under the new letter agreement, the purchase price discount for both Pre-Market and Post-Market Purchases is set at 5.0% of the VWAP
Peraso Inc., a Delaware corporation, filed a Regulation D Form D notice for a new exempt offering of equity securities.
The company established a committed equity facility giving it the right, in its sole discretion, to sell up to $25,000,000 of its common stock from time to time. As of the filing, the total amount sold is $0, so the full $25,000,000 remains available. The exemption claimed is under Rule 506(b), and reported finders' fees are $0. The notice is signed by chief financial officer James Sullivam on 2026-07-06, with the first sale yet to occur.
Peraso Inc. has filed an S-1 to register up to 31,750,000 shares of common stock for resale by Roth Principal Investments, LLC under a committed equity facility. Peraso is not selling shares in this prospectus; Roth, as the selling stockholder and an underwriter, will resell any shares it acquires.
Under a Common Stock Purchase Agreement, Peraso may, at its sole discretion, sell up to $25,000,000 of stock to Roth over a period of up to 36 months through various purchase types at VWAP-based prices, generally at a 3%–6% discount. Peraso would use any proceeds for working capital and general corporate purposes.
As of June 23, 2026, Peraso had 15,040,679 shares outstanding. The filing notes a Nasdaq “Exchange Cap” of 3,004,114 shares (19.99% of pre‑agreement shares) unless pricing or stockholder approval conditions are met, and a 4.99% beneficial ownership limit for Roth, highlighting potential dilution if large volumes are issued.
Peraso Inc. entered into a committed equity facility with Roth Principal Investments, allowing the company, at its discretion, to sell up to $25,000,000 of newly issued common stock over a period of up to 36 months after a resale registration statement is declared effective. Purchases can occur in several intraday windows at prices based on the stock’s VWAP, at discounts of 3% for Market Open and Intraday Purchases and 6% for Pre- and Post-Market Purchases. Nasdaq rules cap initial issuances at 3,004,114 shares, or 19.99% of shares outstanding before the agreement, unless pricing conditions or stockholder approval remove this limit, and Roth’s beneficial ownership cannot exceed 4.99%. Peraso plans to use any net proceeds for working capital and to support product development and expansion in drone, defense and tactical communications markets.
Peraso Inc. filed a prospectus supplement to increase the maximum amount of common stock it may sell under its at-the-market offering program with Ladenburg Thalmann to an aggregate of $670,000 of shares. This is on top of approximately $9,370,130 in shares already sold under the same Sales Agreement. The shares are offered under an effective Form S-3 registration statement and related base prospectus, as updated by several prospectus supplements including the new one. Peraso also filed a legal opinion from Mitchell Silberberg & Knupp LLP covering the validity of the shares issued under this program.
PRSO supplements its Form S-3 prospectus to increase the amount available under an At-the-Market sales agreement with Ladenburg Thalmann to permit up to $670,000 aggregate offering price of common stock to be sold from time to time. The supplement states prior sales under the program totaled approximately $9,370,130. The company reports a public float of $27,523,842 based on 14,718,632 shares outstanding as of May 12, 2026 and a last reported Nasdaq sale price of $0.9793 on May 13, 2026. Sales under General Instruction I.B.6 of Form S-3 remain subject to the one-third-of-public-float limit in any 12-month period; PRSO reports it sold $8,502,675 in the prior 12 months under that instruction.
Peraso Inc. reported very weak first-quarter 2026 results while continuing to face serious liquidity pressures. Net revenue fell to $963,000 from $3.9 million a year earlier, mainly due to a sharp drop in memory IC and mmWave product sales, partly offset by higher engineering services.
The company posted a net loss of $2.5 million, compared with a $471,000 loss in the prior-year quarter, and used $2.3 million of cash in operating activities. Cash and cash equivalents were $2.7 million and working capital was $4.0 million as of March 31, 2026.
Management and the auditor both state there is substantial doubt about Peraso’s ability to continue as a going concern, as recurring losses and negative cash flows are expected to persist without additional capital. The company is relying heavily on its at-the-market equity program, which raised about $2.3 million in Q1 and a further $2.1 million after quarter-end. Peraso is also running a strategic review and remains in discussions with Mobix Labs regarding a potential stock-based transaction, with no assurance any deal will occur.